Randomized Trialvery high evidence
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
Lancet (London, England)·April 27, 2024·PMID 38599221
Why it mattersHFpEF with obesity is common and lacks many effective therapies. This analysis strengthens evidence that semaglutide provides meaningful improvements in symptoms, function, and weight loss, offering a potential disease-modifying treatment for this challenging population.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled